Rosuvastatin On Hypertensive Patients With Paroxysmal Atrial Fibrillation

Objective:To observe the effects of rosuvastatin in primary hypertensive patients with paroxysmal atrial fibrillation effect. To explore the affecting factors in hypertensive patients with paroxysmal atrial fibrillation atrial remodeling in patients with improved mechanism and left atrial function, find new methods of preventing and treating hypertension complicated with paroxysmal atrial fibrillation.Methods:hypertension complicated paroxysmal atrial2012June-2012December treatment of fibrillation in patients with80cases, were randomly divided into the treatment group (A) and control group (B) with40cases in each. And into the period of hypertension did not occur in40patients with atrial fibrillation, as normal control group (C). Started in24h patients with atrial fibrillation after cardioversion of atrial fibrillation were in. Group B by oral Aspirin Enteric-coated Tablets100mg,1/d; Nifedipine Controlled Release Tablets30mg,1/d; amiodarone first week200mg/,3/d, second week,200mg/,2/d, third week,200mg,1/d. A group in the control group based on the service Ruishutuofata Ting10mg,1/d. If the blood pressure can not reach the standards with Indapamide Tablets2.5-5mg,1/d. C group received aspirin only100mg1/d; Nifedipine Controlled Release Tablets30mg,1/d. If the blood pressure can not reach the standards with Indapamide Tablets2.5-5mg,1/d orally, three groups were treated for12months. Observation of A group and B group for1years the incidence of paroxysmal AF and persistent AF incidence, and monitoring the three groups before and after treatment of left atrial diameter, blood lipid, Gao Min C-reactive protein (hsCRP), renin, angiotensin-Ⅱ (Angll), interleukin6(IL-6), tumor necrosis factor alpha (TNF-α) and the function of liver and kidneyResults:12months after treatment in three groups:A group atrial fibrillation control efficiency is significantly higher than that in B group, the difference was statistically significant (P<0.05), A group maintenance rate of sinus rhythm, paroxysmal atrial fibrillation recurrence rate, persistent atrial fibrillation rate is low, compared with that of B group, the difference was statistically significant (P<0.05). Before treatment, A group and B group internal diameter of left atrial hsCRP, renin, Angll, IL-6, TNF-α levels compared with the C group were significantly increased (P<0.05), after treatment of A group and B group were lower than the index before treatment, the difference was statistically significant (P<0.05), and the treatment after A group than in B group decreased more significantly, the difference was statistically significant (P<0.05). Group A lipids were significantly improved compared with before treatment, the difference was statistically significant (P<0.05), liver function index showed no significant difference before and after treatment in three groups (P>0.05)Conclusion:atorvastatin therapy on diastolic hypertensive patients with paroxysmal atrial fibrillation treatment on the basis of, can further reduce the recurrence rate of atrial fibrillation, reduce persistent AF incidence, reduce the left atrial diameter, decreased serum hsCRP, IL-6, TNF-α, kidney essence, the level of AngⅡ, no abnormal liver and renal function and other adverse reactions, which is worthy of clinical application...